Keybanc Maintains Overweight on Inspire Medical Systems, Lowers Price Target to $236
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Brett Fishbin maintains an Overweight rating on Inspire Medical Systems (NYSE:INSP) but lowers the price target from $278 to $236.

August 07, 2024 | 7:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Keybanc analyst Brett Fishbin maintains an Overweight rating on Inspire Medical Systems (NYSE:INSP) but lowers the price target from $278 to $236.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100